DMAPT

DMAPT (Dimethylamino Parthenolide), an analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD50 of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effect[1].

Product Specifications

CAS Number

[791595-09-0]

Product Name Alternative

Dimethylamino Parthenolide

UNSPSC

12352005

Target

NF-κB

Type

Reference compound

Related Pathways

NF-κB

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/DMAPT.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 125 mg/mL (ultrasonic) |H2O : 1.1 mg/mL (ultrasonic; warming; heat to 40°C)

Smiles

C[C@]12[C@@](O2)([H])[C@]3([H])[C@](CC/C(C)=C\CC1)([H])[C@@H](C(O3)=O)CN(C)C

Molecular Formula

C17H27NO3

Molecular Weight

293.40

References & Citations

[1]Neelakantan S, et al. Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1) . Bioorg Med Chem Lett. 2009 Aug 1;19 (15) :4346-9.|[2]Mendonca MS, et al. DMAPT inhibits NF-κB activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo. Free Radic Biol Med. 2017 Nov;112:318-326.|[3]Morel KL, et al. Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clin Exp Metastasis. 2018 Oct;35 (7) :649-661.